videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

CEO, Sweden

Claus Thestrup

Ascelia Pharma

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 11 November at 2.00 PM.

During the third quarter, Ascelia Pharma successfully completed its capital increase, allowing the company to focus on preparations for submitting the NDA for Orviglance and engaging with potential partners. In the last quarter of the year (Q4), Ascelia will receive the complete data package from the Orviglance SPARKLE Phase 3 study. Additionally, they will participate in the annual Radiological Society of North America conference in Chicago from December 1-5, 2024, where they will present abstracts from the SPARKLE study in an oral presentation.

You can already now sign up for the event and send in your questions. You don&#x2019;t have to participate live to submit questions for the event. Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 11 November at 2.00 PM. During the third quarter, Ascelia Pharma successfully completed its capital increase, allowing the company to focus on preparations for submitting the NDA for Orviglance and engaging with potential partners. In the last quarter of the year (Q4), Ascelia will receive the complete data package from the Orviglance SPARKLE Phase 3 study. Additionally, they will participate in the annual Radiological Society of North America conference in Chicago from December 1-5, 2024, where they will present abstracts from the SPARKLE study in an oral presentation. Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates &#x2013; Orviglance&#xae; (Mangoral) and Oncoral &#x2013; Orviglance in Phase 3 and Oncoral in clinical development, but for the moment on hold. Ascelia Pharma has its global headquarters in Malm&#xf6;, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE) Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup, 11 October at 09.00 AM.

HC Andersen Capital

Ascelia Pharma - What happened during Q3?

Genmab

Lundbeck

Gubra

MT Højgaard Holding

Sydbank

HCA Morgenbørs 08/12 - Små fald i futures og fokus på Gubra, Genmab og Lundbeck

AKTIER MED FRIIS - UGE 49 2025

GreenMobility

FLSmidth & Co.

Rockwool

Boozt

HCA Morgenbørs 05/12 - Overvejende positive futures-markeder hvor kun Japan er i minus

GreenMobility: What is the investment case in driverless cars

UPM-Kymmene

UPM and Sappi are planning a joint venture in graphic papers

Seneste videoer